However, none of these EGFR conjugate studies has addressed whether these agents are effective in cancers, which are inherently non-responsive to individual or combinational therapies and whether anti-tumor efficacy is altered in tumor cells which harbor oncogenic mutations downstream of EGFR. The gene discussed is EGFR; the disease is neoplasm.